CCR4 and tropical spastic paraparesis: A recent clinical trial using an anti-CCR4 antibody, mogamulizumab, demonstrated a 64.9% reduction in proviral load among HAM patients [37], highlighting its efficacy against CCR4+ HTLV-1-infected cells.